ArticleVaccines2025
Phylogenetic Analysis of a Newcastle Disease Virus Strain Isolated from Domestic Poultry and Its Potential for Vaccine Development in the Republic of Kazakhstan.
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- High-sensitivity multiplex real-time RT-PCR for universal detection and virulence typing of Newcastle disease virus in poultry field samples.Poultry science · 2026Article
- On-site and visual detection of genotype VII Newcastle disease virus based on RT-RPA and CRISPR/Cas13a.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesDespite the availability of Newcastle disease (ND) vaccines, outbreaks have continued to occur for more than six decades, with significant economic consequences for the global poultry industry. The variability of the Newcastle disease virus requires constant monitoring, detection of new cases, and studies of the origin of the pathogen. The aim of this study was to develop an inactivated ND vaccine using a topical strain with different adjuvants and to compare them for stability, harmlessness, immunogenicity, and efficacy.
methodsA phylogenetic study of the F-gene of the ND strain isolated in Kazakhstan was conducted. The strain, which was selected to create a vaccine for the prevention of the disease, was revealed to belong to genotype VII class II and uploaded to GenBank (NCBI). Two different adjuvants, Montanide ISA 70 VG and Montanide ISA 78 VG, were used to create the vaccine. Birds were vaccinated intramuscularly.
resultsEvaluations of antibody titers in the vaccinated groups during the experiment showed that the vaccines induced adequate levels of antibodies to provide protection against the virulent virus. High antibody titers were observed in the hemagglutination inhibition assay (HAI) in the vaccinated groups as early as 14 days post-vaccination in 100% of birds. The average antibody titer in both vaccinated groups exceeded 7 log2, sufficient to prevent clinical signs. None of the vaccinated birds exhibited clinical signs following control infection, whereas unvaccinated birds developed clinical manifestations within three days post-infection, leading to 100% mortality.
conclusionsThe vaccine developed using the epizootic topical strain is stable, harmless, immunogenic, and effective when challenged with a virulent ND virus strain at a dose of 105 EID
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.